# TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

> **NCT03055221** · PHASE4 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 20 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Intravenous Treprostinil

## Key facts

- **NCT ID:** NCT03055221
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-10
- **Primary completion:** 2014-02-25
- **Final completion:** 2014-02-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055221, "TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03055221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*